Viatris Inc. (USD) Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.

Viatris Inc. (USD) Active

1000 Mylan Boulevard, Canonsburg, PA, US, 15317

Stock Price USD

Price Change

Last Dividend USD

C+

Latest Rating

VTRS's stock peer is BAX (Baxter International Inc.)

VTRS's stock peer is BBIO (BridgeBio Pharma, Inc.)

VTRS's stock peer is ELAN (Elanco Animal Health Incorporated)

VTRS's stock peer is EXAS (Exact Sciences Corporation)

VTRS's stock peer is IONS (Ionis Pharmaceuticals, Inc.)

VTRS's stock peer is MRNA (Moderna, Inc.)

VTRS's stock peer is NBIX (Neurocrine Biosciences, Inc.)

VTRS's stock peer is RDY (Dr. Reddy's Laboratories Limited)

VTRS's stock peer is RGC (Regencell Bioscience Holdings Limited)

VTRS's stock peer is ROIV (Roivant Sciences Ltd.)

Healthcare Drug Manufacturers - Specialty & Generic

Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.

80%

Dcf Rating

20%

Return On Equity

20%

Return On Assets

20%

Debt To Equity

20%

Price To Earnings

80%

Price To Book

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
2026-05-22	2026-06-17	0.12	2.88 %	Quarterly
2026-03-09	2026-03-18	0.12	3.38 %	Quarterly
2025-11-24	2025-12-15	0.12	4.54 %	Quarterly
2025-08-22	2025-09-15	0.12	4.51 %	Quarterly
2025-05-23	2025-06-16	0.12	5.79 %	Quarterly
2025-03-10	2025-03-18	0.12	5.05 %	Quarterly
2024-11-22	2024-12-13	0.12	3.59 %	Quarterly
2024-08-23	2024-09-13	0.12	4.08 %	Quarterly
2024-05-24	2024-06-14	0.12	4.56 %	Quarterly
2024-03-11	2024-03-18	0.12	3.92 %	Quarterly
2023-11-24	2023-12-15	0.12	5.12 %	Quarterly
2023-08-24	2023-09-15	0.12	4.36 %	Quarterly
2023-05-24	2023-06-16	0.12	5.19 %	Quarterly
2023-03-09	2023-03-17	0.12	4.55 %	Quarterly
2022-11-23	2022-12-16	0.12	4.34 %	Quarterly
2022-08-24	2022-09-16	0.12	4.63 %	Quarterly
2022-05-24	2022-06-16	0.12	3.96 %	Quarterly
2022-02-24	2022-03-16	0.12	3.14 %	Quarterly
2021-11-23	2021-12-16	0.11	2.52 %	Quarterly
2021-08-24	2021-09-16	0.11	1.49 %	Quarterly
2021-05-24	2021-06-16	0.11	0.72 %	Quarterly
2007-06-29	2007-07-16	0.06	1.30 %	Quarterly
2007-03-30	2007-04-16	0.06	1.14 %	Quarterly
2006-12-29	2007-01-16	0.06	1.21 %	Quarterly
2006-09-29	2006-10-16	0.06	1.20 %	Quarterly
2006-06-30	2006-07-14	0.06	1.17 %	Quarterly
2006-03-31	2006-04-17	0.06	1.00 %	Quarterly
2005-12-30	2006-01-13	0.06	1.04 %	Quarterly
2005-09-30	2005-10-17	0.06	0.96 %	Quarterly
2005-06-30	2005-07-15	0.06	0.78 %	Quarterly
2005-03-31	2005-04-15	0.03	0.68 %	Quarterly
2004-12-31	2005-01-14	0.03	0.68 %	Quarterly
2004-09-30	2004-10-15	0.03	0.67 %	Quarterly
2004-06-30	2004-07-15	0.03	0.56 %	Quarterly
2004-03-31	2004-04-15	0.03	0.45 %	Quarterly
2003-12-31	2004-01-15	0.03	0.38 %	Quarterly
2003-09-30	2003-10-15	0.03	0.35 %	Quarterly
2003-06-30	2003-07-15	0.03	0.36 %	Quarterly
2003-03-31	2003-04-15	0.03	0.42 %	Quarterly
2002-12-31	2003-01-15	0.05	0.51 %	Quarterly
2002-09-30	2002-10-15	0.04	0.48 %	Quarterly
2002-06-30	2002-07-15	0.04	0.54 %	Quarterly
2002-03-29	2002-04-15	0.04	0.53 %	Quarterly
2001-12-31	2002-01-15	0.04	0.43 %	Quarterly
2001-09-30	2001-10-15	0.04	0.51 %	Quarterly
2001-06-30	2001-07-16	0.04	0.57 %	Quarterly
2001-03-30	2001-04-16	0.04	0.64 %	Quarterly
2000-12-31	2001-01-15	0.04	0.63 %	Quarterly
2000-09-30	2000-10-15	0.04	0.58 %	Quarterly
2000-06-30	2000-07-14	0.04	0.94 %	Quarterly
2000-03-31	2000-04-15	0.04	0.61 %	Quarterly
1999-12-31	2000-01-14	0.04	0.64 %	Quarterly
1999-09-30	1999-10-15	0.04	0.90 %	Quarterly
1999-06-30	1999-07-15	0.04	0.63 %	Quarterly
1999-03-31	1999-04-15	0.04	0.58 %	Quarterly
1998-12-31	1999-01-15	0.04	0.55 %	Quarterly
1998-09-30	1998-10-15	0.04	0.55 %	Quarterly
1998-06-30	1998-07-15	0.04	0.50 %	Quarterly
1998-04-01	1998-04-15	0.04	0.68 %	Quarterly
1997-12-31	1998-01-15	0.04	0.78 %	Quarterly
1997-09-30	1997-10-15	0.04	0.71 %	Quarterly
1997-06-30	1997-07-15	0.04	1.07 %	Quarterly
1997-03-31	1997-04-15	0.04	1.05 %	Quarterly
1997-01-02	1997-01-15	0.04	0.95 %	Quarterly
1996-09-30	1996-10-15	0.04	0.93 %	Quarterly
1996-06-30	1996-07-15	0.04	0.93 %	Quarterly
1996-03-31	1996-04-15	0.04	0.76 %	Quarterly
1995-12-31	1996-01-15	0.04	0.62 %	Quarterly
1995-09-29	1995-10-13	0.04	0.72 %	Quarterly
1995-07-03	1995-07-14	0.05	0.67 %	Quarterly
1995-03-31	1995-04-13	0.05	0.60 %	Quarterly
		0.06	0.71 %	Quarterly
		0.05	0.69 %	Quarterly
		0.04	0.75 %	Quarterly
		0.04	0.82 %	Quarterly
		0.04	0.58 %	Quarterly
		0.04	0.48 %	Quarterly
		0.03	0.42 %	Quarterly
		0.03	0.41 %	Quarterly
		0.03	0.37 %	Quarterly
		0.03	0.39 %	Quarterly
		0.05	0.55 %	Quarterly
		0.05	0.53 %	Quarterly
		0.05	0.52 %	Quarterly
		0.05	0.61 %	Quarterly
		0.05	0.79 %	Quarterly
		0.05	0.75 %	Quarterly
		0.05	0.76 %	Quarterly
1990-09-30	1990-10-15	0.05	0.83 %	Quarterly
1990-06-30	1990-07-16	0.05	0.44 %	Semi-Annual
1989-12-26	1990-01-15	0.05	0.41 %	Semi-Annual
1989-06-30	1989-07-17	0.05	0.71 %	Semi-Annual
1988-12-30	1989-01-16	0.03	0.88 %	Semi-Annual
1988-07-06	1988-07-15	0.05	0.77 %	Semi-Annual
1987-12-31	1988-01-15	0.05	1.13 %	Semi-Annual
1987-06-30	1987-07-15	0.05	0.64 %	Semi-Annual
1986-12-31	1987-01-15	0.05	0.44 %	Semi-Annual

Recent News

U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain

FDA PDUFA Goal Date Set for Dec. 27, 2026 PITTSBURGH, May 18, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MR-107A-02 (fast-acting meloxicam), a non-opioid, for the treatment of moderate-to-severe acute pain. The FDA has assigned a PDUFA goal date of Dec. 27, 2026.

2026-05-18 08:00:00

Viatris to Present at the Bank of America Securities 2026 Healthcare Conference

PITTSBURGH, May 7, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will present at the Bank of America Securities 2026 Healthcare Conference on Tuesday, May 12, 2026, at 8 a.m. PT / 11 a.m.

2026-05-07 16:30:00

Viatris Reports First-Quarter 2026 Financial Results

Delivers Total Revenues of $3.5 Billion, Representing 8% Reported Growth Compared to First Quarter 2025, and U.S. GAAP Net Earnings of $176 Million Total Revenues Were Up 3% Operationally Compared to First Quarter 2025 Adjusted EBITDA was $1.0 Billion Up 10% Operationally Compared to First Quarter 2025, Demonstrating Solid Operating Leverage Progresses Key Launches and Pipeline Milestones Across Multiple Products, Including the Launch of Effexor® for Generalized Anxiety Disorder in Japan Continues to Expect More Than $2.5 Billion of Cash Available for Deployment in 2026 Reaffirms 2026 Financial Guidance [1] PITTSBURGH, May 7, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced its first-quarter 2026 financial results. Executive Commentary "We delivered a strong first quarter, reflecting disciplined execution across our global businesses," said Scott A.

2026-05-07 06:59:00

Viatris Announces Quarterly Dividend

PITTSBURGH, May 5, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on May 4, 2026, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on June 17, 2026, to shareholders of record as of the close of business on May 22, 2026.

2026-05-05 06:59:00

Viatris Announces Chief Financial Officer Transition

Theodora "Doretta" Mistras to Depart; Paul Campbell Named Interim CFO PITTSBURGH, May 4, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Theodora "Doretta" Mistras, Chief Financial Officer, will depart the Company for a new professional opportunity. Viatris has named Paul Campbell, currently Chief Accounting Officer and Corporate Controller, as interim Chief Financial Officer, effective May 8, 2026, while the Company conducts its search for a permanent successor.

2026-05-04 16:30:00

Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting

PITTSBURGH, May 1, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that six abstracts on its investigational low-dose estrogen combined hormonal contraceptive (CHC) weekly patch will be presented at the 2026 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting (ACSM) in Washington, D.C., May 1-3, 2026.

2026-05-01 06:59:00

Viatris to Report First Quarter 2026 Financial Results on May 7, 2026

PITTSBURGH, April 13, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report first quarter 2026 financial results on Thursday, May 7, 2026. Company executives will host a webcast at 8:30 a.m.

2026-04-13 06:59:00

Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting

PITTSBURGH, April 10, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that four abstracts will be presented at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, D.C., April 10-13, 2026.

2026-04-10 06:59:00

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions